Qvar Redihaler

— THERAPEUTIC CATEGORIES —
  • Asthma/COPD

Qvar Redihaler Generic Name & Formulations

General Description

Beclomethasone dipropionate HFA 40mcg, 80mcg; per actuation; breath-actuated inhalation aerosol with a dose counter.

Pharmacological Class

Steroid.

How Supplied

Inhalation aerosol (w. dose counter)—10.6g (120 inh)

Manufacturer

Generic Availability

NO

Qvar Redihaler Indications

Indications

Maintenance treatment of asthma as prophylactic therapy.

Limitations of Use

Not for the relief of acute bronchospasm.

Qvar Redihaler Dosage and Administration

Adult

Previously not on inhaled corticosteroids: initially 40–80mcg twice daily (approx. 12hrs apart). Previously on inhaled corticosteroids: initially 40–320mcg twice daily. Both: if insufficient response after 2 weeks, increasing the dose may provide additional asthma control; max 320mcg twice daily. Titrate to lowest effective dose after stability achieved. Rinse mouth after use.

Children

<4yrs: not established. 4–11yrs: initially 40mcg twice daily (approx. 12hrs apart). If insufficient response after 2 weeks, increasing the dose may provide additional asthma control; max 80mcg twice daily. Titrate to lowest effective dose after stability achieved. Rinse mouth after use.

Qvar Redihaler Contraindications

Contraindications

Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures.

Qvar Redihaler Boxed Warnings

Not Applicable

Qvar Redihaler Warnings/Precautions

Warnings/Precautions

Do not exceed recommended dose. Risk of local infections (eg, mouth/pharynx candidiasis). Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Immunosuppression: active or quiescent tuberculosis, systemic infections, ocular herpes simplex. If exposed to chickenpox or measles, consider immune globulin or antiviral ­prophylactic therapies. Monitor for signs/symptoms of adrenal insufficiency when transferring from systemic corticosteroids. May need supplemental systemic corticosteroids during periods of stress or a severe asthma attack. May unmask previously suppressed allergic conditions. Eosinophilic conditions. Reevaluate periodically. Monitor for hypercorticism and HPA axis suppression (if occurs, discontinue gradually), growth in children, or any visual changes. Discontinue if paradoxical bronchospasm occurs; use alternative therapy. Assess bone mineral density if risk factors exist (eg, prolonged immobilization, osteoporosis, or chronic use of drugs that can reduce bone mass [eg, anticonvulsants, oral steroids]). Elderly. Pregnancy: monitor closely. Nursing mothers.

Qvar Redihaler Pharmacokinetics

See Literature

Qvar Redihaler Interactions

Not Applicable

Qvar Redihaler Adverse Reactions

Adverse Reactions

Oral candidiasis, upper respiratory tract infection, nasopharyngitis, allergic rhinitis, oropharyngeal pain, sinusitis; rare: hypersensitivity reactions, psychiatric events and behavioral changes (esp. in children).

Qvar Redihaler Clinical Trials

See Literature

Qvar Redihaler Note

Not Applicable

Qvar Redihaler Patient Counseling

See Literature

Images